Does the CYTOKINETICS (CYTK) Form 4 show any insider share sales?

The filing does not report any sales. All reported transactions are coded “A” for grant or award acquisitions, covering 2,851 common shares and a 4,301-share non-qualified option, indicating an increase in the director’s potential and actual equity exposure, not a reduction.

CYTOKINETICS (CYTK) director awarded shares and new 4,301-share stock option

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

CYTOKINETICS INC director Muna Bhanji received new equity compensation. On 2026-05-27, Bhanji was granted 2,851 shares of common stock at no cost, increasing direct holdings to 26,361 shares.

Bhanji was also awarded a non-qualified stock option for 4,301 shares of common stock at an exercise price of $77.15 per share. The option becomes exercisable on 2026-06-28 and expires on 2036-05-26.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Bhanji Muna

Role null

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (Right to Buy)	4,301	$0.00	--
Grant/Award	Common Stock	2,851	$0.00	--

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 4,301 shares (Direct, null); Common Stock — 26,361 shares (Direct, null)

Footnotes (1)

Key Figures

Restricted stock grant: 2,851 shares Shares held after grant: 26,361 shares Option grant size: 4,301 shares +3 more

6 metrics

Restricted stock grant 2,851 shares Common stock awarded on May 27, 2026

Shares held after grant 26,361 shares Common stock directly owned post-transaction

Option grant size 4,301 shares Non-qualified stock option linked to common stock

Option exercise price $77.15 per share Conversion/exercise price for new option

Option vesting date June 28, 2026 Date option becomes exercisable

Option expiration May 26, 2036 Expiration date of non-qualified stock option

Key Terms

Non-Qualified Stock Option, exercise price, Grant, award, or other acquisition, Form 4

4 terms

Non-Qualified Stock Option financial

"Non-Qualified Stock Option (Right to Buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

exercise price financial

"conversion_or_exercise_price": "77.1500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/27/2026 - 07:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bhanji Muna

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/27/2026		A		2,851	A	$0	26,361	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (Right to Buy)	$77.15	05/27/2026		A		4,301		06/28/2026	05/26/2036	Common Stock	4,301	$0	4,301	D

Explanation of Responses:

	/s/ John Faurescu, atttorney-in-fact for Ms. Bhanji	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did CYTOKINETICS (CYTK) director Muna Bhanji report?

Director Muna Bhanji reported receiving 2,851 shares of CYTOKINETICS common stock and a non-qualified stock option for 4,301 shares. These awards are compensation grants, not open-market purchases or sales, and increase her direct equity exposure to the company.

How many CYTOKINETICS (CYTK) shares does Muna Bhanji hold after this Form 4?

After the reported grant, Muna Bhanji directly holds 26,361 shares of CYTOKINETICS common stock. This figure reflects the newly awarded 2,851 shares added to her prior holdings, providing a clearer picture of her current direct ownership stake in the company.

What are the key terms of Muna Bhanji’s new CYTOKINETICS stock option?

The new non-qualified stock option covers 4,301 CYTOKINETICS shares at an exercise price of $77.15 per share. It is scheduled to become exercisable on June 28, 2026, and will expire on May 26, 2036 if not exercised before that date.

Is Muna Bhanji’s CYTOKINETICS Form 4 a buy or a grant?

The Form 4 reflects grant and award acquisitions, not open-market buying. Bhanji received 2,851 shares and a 4,301-share non-qualified option as equity compensation awards, both reported with transaction code “A” for grants or other acquisitions from the issuer.